OCUGEN INC. - COMMON STOCK

Ocugen to Present at Investing in Cures Summit

06 مارس 2024 06:30:09 بحسب Nasdaq GlobeNewswire

Ocugen Clinical Showcase Webcast Now Available

28 فبراير 2024 07:00:26 بحسب Nasdaq GlobeNewswire

Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit

26 فبراير 2024 07:30:13 بحسب Nasdaq GlobeNewswire

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

22 فبراير 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Ocugen to Present at 2024 BIO CEO & Investor Conference

21 فبراير 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024

14 فبراير 2024 06:30:49 بحسب Nasdaq GlobeNewswire

Ocugen to Present at Pharma Market Research Conference

31 يناير 2024 07:00:12 بحسب Nasdaq GlobeNewswire

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

16 يناير 2024 06:30:58 بحسب Nasdaq GlobeNewswire

Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design

21 ديسمبر 2023 05:30:09 بحسب Nasdaq GlobeNewswire

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

19 ديسمبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

13 ديسمبر 2023 06:30:14 بحسب Nasdaq GlobeNewswire

Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

29 نوفمبر 2023 06:30:12 بحسب Nasdaq GlobeNewswire

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

10 نوفمبر 2023 06:30:37 بحسب Nasdaq GlobeNewswire

Ocugen Provides Business Update with Third Quarter 2023 Financial Results

09 نوفمبر 2023 05:30:00 بحسب Nasdaq GlobeNewswire

Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit

07 نوفمبر 2023 06:45:14 بحسب Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results

02 نوفمبر 2023 06:30:06 بحسب Nasdaq GlobeNewswire

Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

10 أكتوبر 2023 05:30:48 بحسب Nasdaq GlobeNewswire

Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa

04 أكتوبر 2023 06:00:20 بحسب Nasdaq GlobeNewswire

Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference

29 سبتمبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference

27 سبتمبر 2023 18:30:50 بحسب Nasdaq GlobeNewswire